December 24, 2015

Evogene appoints new chief financial officer

Evogene Ltd. has announced the appointment of Eyal Leibovitz as the company's chief financial officer.

He will join Evogene on January 1, 2016, and replace Sigal Fattal who has been with the company since June 2012.

Fattal will remain in the company until January 31 to ensure a smooth transition.

Leibovitz reports to Ofer Haviv, Evogene's president and chief executive officer, and will be responsible for all corporate functions in the company.

"Eyal has an impressive track record as a CFO in both private and public companies. In his prior roles, Eyal has proven himself a key member of executive management teams with direct responsibility for finance, M&A and business development," said Haviv. 

"(Leibovitz's) record clearly demonstrates the skills and experience necessary to help guide our company's growth and continued diversification. In addition, a key objective for Eyal will be to increase the awareness in the US financial market of Evogene's unique capabilities in providing next generation products for the enhancement of agriculture and our rapidly growing presence in multiple key market areas."

Leibovitz brings with him an extensive background in senior management, finance, investor relations, M&A and business development in international companies headquartered in both Israel and the US.

He last served as CFO and was a member of the executive committee of N-trig Ltd., an electronic inking company. In his previous appointments, he functioned as CFO of Kamada Ltd. and international controller of Harmonic Inc.

Leibovitz holds a BBA degree from the City University of New York.